Announcements Trials
Browse Landscape

Phase

Phase 1/2 5Phase 1 2Phase 2 1

Status

Completed 5

Sponsor Class

NIH 4OTHER 1

Study Type

Interventional 5

Sponsor

Cancer Type

Sarcoma 5CNS 5

Conditions

Glioblastoma 6Gliosarcoma 5Brain Neoplasms 5Prostatic Neoplasms 4Oligodendroglioma 3Lymphoma, Non-Hodgkin 3Lymphoma, Mantle-Cell 3Lymphoma, Follicular 3Glioma 3Astrocytoma 3Waldenstrom Macroglobulinemia 2Lymphoma, B-Cell, Marginal Zone 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Urinary Bladder Neoplasms 1Urethral Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma, Synovial 1Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma 1Pancreatic Neoplasms 1Osteosarcoma 1Neurofibrosarcoma 1Neoplasms, Squamous Cell 1Neoplasms 1Neoplasm Metastasis 1Multiple Myeloma 1Lymphoma, T-Cell 1

Interventions

Temozolomide 23Radiotherapy 15Radiation 7Bevacizumab 6temsirolimus 5Sirolimus 5Radiotherapy, Conformal 5Erlotinib Hydrochloride 5Carmustine 5Carboplatin 5Radiotherapy, Intensity-Modulated 4Everolimus 4Vorinostat 3Irinotecan 3veliparib 2tipifarnib 2plerixafor 2pembrolizumab 2atezolizumab 2Surgical Procedures, Operative 2Sorafenib 2Gefitinib 2Fluorodeoxyglucose F18 2Cilengitide 2Chemotherapy, Adjuvant 2vatalanib 1vandetanib 1terameprocol 1tandutinib 1romidepsin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 1/2 × Gliosarcoma × temsirolimus × Clear all
NCT01051557 2021-07-19

Temsirolimus and Perifosine in Treating Patients With Recurrent or Progressive Malignant Glioma

National Cancer Institute (NCI)

Phase 1/2 Completed
36 enrolled 15 charts
CNSSarcoma

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Oligodendroglioma, Gliosarcoma

NCT00329719 2018-10-16

Sorafenib Tosylate and Temsirolimus in Treating Patients With Recurrent Glioblastoma

National Cancer Institute (NCI)

Phase 1/2 Completed
115 enrolled 13 charts
CNSSarcoma

Brain Neoplasms, Glioblastoma, Gliosarcoma

NCT00335764 2018-07-02

Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma

National Cancer Institute (NCI)

Phase 1/2 Completed
92 enrolled 24 charts
CNSSarcoma

Brain Neoplasms, Glioblastoma, Gliosarcoma

NCT00022724 2018-06-26

CCI-779 in Treating Patients With Malignant Glioma

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 1/2 Completed
49 enrolled
CNSSarcoma

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Oligodendroglioma, Central Nervous System Neoplasms, Gliosarcoma

NCT00112736 2015-06-15

Erlotinib and Temsirolimus in Treating Patients With Recurrent Malignant Glioma

National Cancer Institute (NCI)

Phase 1/2 Completed
69 enrolled 12 charts
CNSSarcoma

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Oligodendroglioma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡